Prevymis (Letermovir) Patent Expiration, LOE Window & CMS Spending

Prevymis (Letermovir) by Merck & Co.: FDA Orange Book core substance LOE 2029-01-18 (last listed 2031-08-30), 0 AB generics, $154.7M 2024 CMS Part D & Medicaid spend, and $2,058 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN209939 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-01-18
Last Listed Patent or Exclusivity Date2031-08-30
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$154.7M
2024 Medicare Part D Spend$120.5M
2024 Medicaid Spend$34.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,058 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.